Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD)

NCT ID: NCT00300118

Last Updated: 2014-05-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 311 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2004-09-30
• Study Completion Date: 2008-05-31

Brief Summary

The purpose of this study is to determine whether mesalazine or budesonide is more active in the treatment of active Crohn's disease.

Detailed Description

Crohn's disease is often treated with glucocorticoids or mesalazine. Both drugs are indicated for active Crohn's disease. Treatment with mesalazine is indicated for the treatment of mildly to moderately active Crohn's disease. Budesonide 9 mg/day or mesalazine 4.5 g/day are better than lower doses.

So far only one trial compares the efficacy and safety of budesonide and 5-ASA. The result of this trial is that budesonide is more effective in inducing remission than mesalazine. The primary objective of this trial is to confirm this result for other presentations of budesonide and mesalazine; i.e. Budenofalk® capsules (9 mg/day) and Salofalk® tablets (Eudragit-L-coated oral mesalazine; 4.5 g/day) in moderately active Crohn's disease. Mesalazine is used in this trial as a comparator.

Conditions

Crohn's Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

A

Group Type: EXPERIMENTAL

budesonide

Intervention Type: DRUG

9 mg

B

Group Type: ACTIVE_COMPARATOR

mesalazine

Intervention Type: DRUG

4.5 g

Interventions

budesonide

9 mg

Intervention Type: DRUG

mesalazine

4.5 g

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Symptoms of Crohn's disease since at least 3 months; diagnosis confirmed by endoscopic and histological, or endoscopic and radiological criteria [endoscopy not older than 12 months or if older, then clinical signs (e.g. pain localization, pain intensity, blood in stool) and behaviour (according to Vienna classification) should be unchanged compared to former episodes]
• Localisation of CD either in terminal ileum, ascending colon or ileocolitis
• Active phase of disease (200 < CDAI < 400)

Exclusion Criteria

• Known Crohn's lesion in the upper GI-tract (up to and including the jejunum) with present symptoms
• CD in the rectum currently present
• Short bowel syndrome
• Septic complications
• Baseline stool positive for germs causing bowel disease
• Abscess, perforation or active fistulas
• Ileostomy or colostomy
• Resection of more than 50 cm of the ileum
• Bowel surgery within the last 3 months
• Immediate surgery required
• Clinical signs of stricturing disease
• Subileus within the last 6 months
• Suspicion of ileus, subileus or corresponding symptomatology
• Contra-indications, special warnings and precautions mentioned in SmPC
• Treatment with immunosuppressants, cytostatics, 6-TG, methotrexate, or cyclosporine within the last 3 months; in case of treatment with azathioprine or 6-MP the drugs have to be used for maintenance of remission only and dosage has to be unchanged within the last 3 months before baseline visit and during the study
• Treatment with ketoconazole, ciprofloxacin or other CYP3A inhibitors within the last month before baseline visit
• Treatment with anti-TNF-a therapy within 6 months before baseline visit
• Conventional steroids (iv, po, rectal) within 2 weeks before the study
• > 6 mg/d budesonide po or > 3 g/d mesalazine po within 2 weeks before the study
• Patients known to be steroid-refractory or steroid-dependent from former CD episodes
• Treatment of study disease with oral antibiotics (e.g., metronidazole) within the last 2 weeks

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Dr. Falk Pharma GmbH

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Andreas Tromm, Professor

Role: PRINCIPAL_INVESTIGATOR

Ev. Krankenhaus Hattingen GmbH

Locations

Ev. Krankenhaus Hattingen GmbH

Hattingen, , Germany

Countries

Germany

References

Tromm A, Bunganic I, Tomsova E, Tulassay Z, Lukas M, Kykal J, Batovsky M, Fixa B, Gabalec L, Safadi R, Kramm HJ, Altorjay I, Lohr H, Koutroubakis I, Bar-Meir S, Stimac D, Schaffeler E, Glasmacher C, Dilger K, Mohrbacher R, Greinwald R; International Budenofalk Study Group. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease. Gastroenterology. 2011 Feb;140(2):425-434.e1; quiz e13-4. doi: 10.1053/j.gastro.2010.11.004. Epub 2010 Nov 9.

Reference Type: RESULT

PMID: 21070781 (View on PubMed)

Other Identifiers

2004-001213-34

Identifier Type: -

Identifier Source: secondary_id

BUC-52/CDA

Identifier Type: -

Identifier Source: org_study_id